One Stop Solution For In-Depth Market Research Reports


Home    >    HEALTHCARE AND PHARMACEUTICALS   >   Pigmentation Disorders Treatment Market

[ 英語タイトル ] Pigmentation Disorders Treatment Market - Growth, Trends, and Forecasts (2020 - 2025)

Product Code : MDHC0089147
Survey : Mordor Intelligence
Publish On : November, 2020
Number of Pages : 112
Category : Healthcare and Pharmaceuticals
Study Area : Global
Report format : PDF
Sales price option (consumption tax not included)
Single User USD4250 / Question Form
5 User USD4750 / Question Form
Enterprise User USD7500 / Question Form
 - AbbVie Inc (Allergan, Inc)
- Episciences, Inc.
- Dermamed Solutions
- La Roche-Posay
- Pierre Fabre Laboratories
- SkinCeuticals International
- Obagi Cosmeceuticals LLC
- Alvogen, Inc.
- Galderma laboratories (Nestle Skin Health S.A)
- Merz Pharma

[Report Description]

The Pigmentation Disorders Treatment Market is expected to grow with a CAGR of 9.7% during the forecasted period. The key factors propelling the growth of this market are rising up-gradation of lifestyle coupled with the increasing demand for skin lightening is a major factor anticipated to drive the global pigmentation disorder treatment market. Additionally, increasing the aging population, increasing incidence of skin disorders, and growing disposable income are the few other factors boosting the global pigmentation disorder treatment market.

As per Vitiligo Research Foundation latest data 2020, the total number of people suffering from vitiligo is estimated at around 65-95 million people worldwide. However, the actual number may be much higher because vitiligo is an underreported disease. Furthermore, the high adoption of cosmetic procedures and skin care products is also anticipated to drive market growth during the forecast period. However, high costs and side effects associated with cosmetic procedures and unfavorable reimbursement is restraining the market growth.

Key Market Trends

Topical Treatment Segment is Expected to Hold Significant Market Share Over the Forecast Period

- Currently, topical treatment is dominating the global market due to the improved clinical outcomes in patients suffering from pigmentation disorders. The most common topical drugs prescribed globally are azelaic acid, hydroquinone, L-ascorbic acid, etc. Topical therapy includes hydroquinone as a first-line agent also with a retinoid for treatment of melasma due to its highest rate in the white population.
- As per National Clinical Trials (NCT) registry, as of June 18, 2020, Incyte Corporation is conducting a clinical trial for Ruxolitinib in the treatment of Vitiligo which is in phase II development in the United States. This factor will boost the market if Ruxolitinib drug gets approved for the treatment of Vitiligo in the near future.
- Chemical peels have found prominence in the past decades to treat facial hyperpigmentation disorders. Chemical peels are the products in which a chemical solution is applied to the face, neck, and hands to exfoliate the dead skin cells, stimulate the growth of new skin cells and followed by the release of cytokines and inflammatory mediators, resulting in thickening of the epidermis, deposition of collagen, reorganization of structural elements, and increases in dermal volume.
- This process reduces solar elastosis, replaces and reorients the new dermal connective tissue, resulting in an enhanced clinical appearance of the skin, with fewer rhytides and reduced pigmentary dyschromia, and a more youthful appearance.
- Thus, owing to above mentioned factors the segment is expected to show significant growth over the forecast period.

North America is Expected to Dominate the Global Pigmentation Disorders Treatment Market

- North America dominates the global pigmentation disorders treatment market owing to the rising pigmentation disorders. Presence of well-established healthcare infrastructure and major market players providing effective treatment options to the patients suffering from post-inflammatory hyperpigmentation in North America.
- As per the National Organization for Albinism and Hypopigmentation 2018, in the United States, about one in 18,000 to 20,000 people had some type of albinism. In other parts of the world, the occurrence can be as high as one in 3,000.
- Asia Pacific region is experiencing a swift pace in the global pigmentation disorders treatment market due to the increasing beauty consciousness among Asians, rapid entry of new players into the market and expansion by the major players into the emerging economies.

Competitive Landscape

The Pigmentation Disorders Treatment Market is fragmented competitive. The major players are focused on expanding their business in different areas by adopting various market strategies such as partnerships, collaborations, acquisitions, and mergers, etc. Key developments in the market include in July 2019, Dermatix, a brand of A.Menarini Singapore Pte Ltd has just launched its new acne scar care, Dermatix Acne scar consisting of snail slime extract and Hyaluronic Acid combating post-acne skin discoloration, the treatment gel contains Niacinamide (Vitamin B3) to reduce hyperpigmentation.

Reasons to Purchase this report:

- The market estimate (ME) sheet in Excel format
- 3 months of analyst support

1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study



4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Prevalence and of Pigmentation Disorders
4.2.2 Growing Expenditure on the Dermatalogical Treatments
4.3 Market Restraints
4.3.1 High Cost of the Cosmetic procedures
4.3.2 Inadequate Reimbursement Policies
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry

5.1 By Type of Disorder
5.1.1 Albinism
5.1.2 Vitiligo
5.1.3 Melasma
5.1.4 Post-Inflammatory Hyperpigmentation (PIH)
5.1.5 Other Type of Disorders
5.2 Treatment Type
5.2.1 Topical Treatment
5.2.2 Dermabrasion
5.2.3 Chemical peels
5.2.4 Laser Treatment
5.2.5 Phototherapy
5.2.6 Other Treatment Types
5.3 Geography
5.3.1 North America United States Canada Mexico
5.3.2 Europe Germany United Kingdom France Italy Spain Rest of Europe
5.3.3 Asia-Pacific China Japan India Australia South Korea Rest of Asia-Pacific
5.3.4 Middle-East and Africa GCC South Africa Rest of Middle-East and Africa
5.3.5 South America Brazil Argentina Rest of South America

6.1 Company Profiles
6.1.1 AbbVie Inc (Allergan, Inc)
6.1.2 Episciences, Inc.
6.1.3 Dermamed Solutions
6.1.4 La Roche-Posay
6.1.5 Pierre Fabre Laboratories
6.1.6 SkinCeuticals International
6.1.7 Obagi Cosmeceuticals LLC
6.1.8 Alvogen, Inc.
6.1.9 Galderma laboratories (Nestle Skin Health S.A)
6.1.10 Merz Pharma




Recommended reports